NasdaqCM - Delayed Quote • USD
Galmed Pharmaceuticals Ltd. (GLMD)
As of April 22 at 4:00 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | 0 | 0 | -1.29 | -1.03 |
| Low Estimate | 0 | 0 | -1.29 | -1.03 |
| High Estimate | 0 | 0 | -1.29 | -1.03 |
| Year Ago EPS | -1.09 | -0.95 | -2.5 | -1.29 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.5 | -0.34 | -0.27 | -0.32 |
| EPS Actual | -1.09 | -0.95 | -0.24 | -0.98 |
| Difference | 0.41 | -0.61 | 0.03 | -0.66 |
| Surprise % | 27.30% | -179.40% | 11.10% | -206.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | -1.29 | -1.03 |
| 7 Days Ago | 0 | 0 | -1.29 | -1.03 |
| 30 Days Ago | 0 | 0 | -1.29 | -1.03 |
| 60 Days Ago | 0 | 0 | -1.29 | -1.03 |
| 90 Days Ago | 0 | 0 | -1.29 | -1.03 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | GLMD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 1.30% |
| Next Qtr. | -- | -- | -- | 10.60% |
| Current Year | 48.40% | -- | -- | 5.10% |
| Next Year | 20.20% | -- | -- | 13.40% |
| Next 5 Years (per annum) | 20.00% | -- | -- | 11.21% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | Maxim Group: Hold to Buy | 7/24/2023 |
| Downgrade | Maxim Group: Buy to Hold | 8/8/2022 |
| Downgrade | Canaccord Genuity: Buy to Hold | 8/8/2022 |
| Downgrade | Raymond James: Outperform to Market Perform | 5/18/2022 |
| Downgrade | HC Wainwright & Co.: Buy to Neutral | 5/3/2022 |
| Maintains | Raymond James: Outperform | 5/3/2022 |
Related Tickers
TCON TRACON Pharmaceuticals, Inc.
1.8500
+1.65%
CNTB Connect Biopharma Holdings Limited
1.3299
-1.49%
TENX Tenax Therapeutics, Inc.
3.5900
+1.13%
VRPX Virpax Pharmaceuticals, Inc.
3.2200
-3.01%
MBIO Mustang Bio, Inc.
0.3470
+2.06%
GALT Galectin Therapeutics Inc.
3.0600
0.00%
RNAZ TransCode Therapeutics, Inc.
0.4654
+1.42%
KZIA Kazia Therapeutics Limited
0.3830
0.00%
PASG Passage Bio, Inc.
1.1500
+0.88%
DRMA Dermata Therapeutics, Inc.
0.3514
+3.78%